Symbiotix has licensed more Harvard IP to propel the commercialisation of T-cell modulators based on studies of the human microbiome.

Symbiotix Biotherapies, a US-based molecular therapeutics developer advancing research from several institutions, has secured an additional licence for intellectual property from Harvard University.

Founded in 2009, Symbiotix is working on Reglemers, a type of T-cell modulator intended to provide relief for patients living with autoimmune and inflammatory diseases. The approach relies on molecules originating from the human microbiome, an internal microorganism network increasingly regarded as crucial to developing new therapies.

The new licences commercialise more work performed by Symbiotix scientific…